Press release - FDR Amulet Innovality


FDR AMULET Innovality: Innovation and Quality in Mammography

Volumetric solutions including 3D Mammography, Tomosynthesis and Biopsy in one system. At the European Congress of Radiology (ECR) 2013 which is held from 7 to 11 March in Vienna, Austria, FUJIFILM Europe will present an addition to its lineup of AMULET systems. The new FDR AMULET Innovality will support all known volumetric methods within one device with a superior image level, reduced dose and improved patient comfort.

The FDR AMULET Innovality integrates a range of 3D applications in mammography examinations. Different tomosynthesis modes with variable dose and angulation are possible, allowing the user to be more flexible according to the clinical scenario.
Advanced 3D visualization is also available using two high-resolution images taken from different angles as a dose efficient improvement of routine diagnosis.

The system is equipped with a completely new amorphous selenium (a-Se) detector, utilizing a revolutionary detector geometry with Hexagon Close Pattern (HCP) technology. This unique detector design leads to superior image sharpness and dose efficiency. The detector structure provides approximately 20% dose reduction compared with the previous one, which was already one of the most efficient systems on the market. At the same time, the level of image detail makes the system unique and a particularly attractive proposition.

In addition to the high technological standard, the new system was optimized for improved user ergonomics and better patient comfort. A remarkable reduction in pain during mammography examinations is now possible using new breast adaptive compression paddles.

The innovative intelligent automatic exposure control can be used even in the presence of implants, leading to improved workflow and the higher diagnostic value of routine mammography.

By using 3D Mammography for routine examinations the incidence of false positive diagnosis can be dramatically reduced without a significant increase in dose. Respective preliminary studies conducted in several countries have shown a reduction of
up to 40% in false positives. This is reflected in a significant reduction in the number of biopsies and a related reduction of unnecessary stress for doctors and patients alike. Further classification and evaluation of findings can be performed with using either one of two modes of Tomosynthesis for maximum dose reduction and best diagnostic quality.This allows for maximum confidence in reporting. 

At ECR 2013 AMULET Innovality will be presented as a work in progress product. The Fujifilm booth is located at the Austria Center Vienna, Expo B, Booth Nr. 210.

About FUJIFILM Corporation
Fujifilm Corporation is one of the major operating companies of Fujifilm Holdings. Since its founding in 1934, the company has built up a wealth of advanced technologies in the field of photo imaging, and in line with its efforts to become a comprehensive healthcare company, Fujifilm is now applying these technologies to the prevention, diagnosis and treatment of diseases in the Medical and Life Science fields. Fujifilm is also expanding growth in the highly functional materials business, including flat panel display materials, and in the graphic systems and optical devices businesses. For more information, please visit

About Fujifilm in Europe
Nowadays Fujifilm entities operate in over 50 group companies in Europe and employ more than 5,000 people engaged in R&D, manufacturing, sales, and service support. Throughout Europe they serve a range of industries including medical, chemical, graphic arts, electronic materials, optics, recording media, motion picture, and photographic technologies. Fujifilm Europe GmbH (Duesseldorf, Germany) acts as Strategic Headquarters for the region and supports its group companies in Europe by formulating marketing and corporate strategies. For more information, please visit 

2017 Fujifilm Sverige